Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

Hunan Province Tumor Hospital200 enrolled

Overview

Non-small cell lung cancer patients may have brain metastases at diagnosis. Patients with brain metastasis may contribute as poor prognosis factors. This trial aims to explore the efficacy and the safety of immune checkpoint inhibitors in non small cell lung cancer patients with initial brain metastasis.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Non Small Cell Lung Cancer

Interventions

immune therapyDRUG

The patient receives immunotherapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis 3. Treated with ICIs Exclusion Criteria: * 1.Patients with a clear driver mutation that can be targeted for first-line treatment

Locations (1)

Hunan Cancer Hospital

Changsha, Hunan, China

Outcomes

Primary Outcomes

ORR

disease remission rate

Time frame: November 2017- October 2021

PFS

progression free survival

Time frame: November 2017- October 2021

Secondary Outcomes

Overall survival

Time frame: November 2017- October 2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.